63 citations
,
July 2024 in “Journal of the American Academy of Dermatology” This study found that the oral JAK1/JAK2 inhibitor deuruxolitinib effectively promoted hair regrowth and patient satisfaction in adults with alopecia areata over 24 weeks.
4 citations
,
September 2025 in “Journal of the American Academy of Dermatology” The trial helped find the best dose of deuruxolitinib for treating alopecia areata.
3 citations
,
November 2024 in “Clinical Research” This article discusses the immune mechanisms involved in alopecia areata, focusing on T-cell activity and cytokine-driven JAK signaling, but reports no new clinical results.
2 citations
,
November 2025 in “Journal of the American Academy of Dermatology” In this randomized, placebo-controlled trial, adults with severe chronic alopecia areata who received deuruxolitinib showed significant hair regrowth compared to placebo over 24 weeks, and the treatment was generally well-tolerated, though long-term effects remain unexamined.
2 citations
,
October 2025 in “Frontiers in Medicine” This study found that deuruxolitinib may effectively improve hair regrowth and patient satisfaction in moderate to severe alopecia areata, but careful monitoring is needed due to manageable side effects and concerns about long-term safety.
2 citations
,
September 2024 in “Journal of the American Academy of Dermatology” Deuruxolitinib significantly helps regrow scalp hair in adults with moderate to severe alopecia areata.
2 citations
,
September 2024 in “Journal of the American Academy of Dermatology” Deuruxolitinib is generally safe for treating alopecia areata.
2 citations
,
September 2023 in “Journal of the American Academy of Dermatology” CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.
1 citations
,
February 2025 in “Journal of the American Academy of Dermatology” Most men prefer keeping their eyebrows over scalp hair.
In this reported case, a 30-year-old man with a long history of alopecia universalis experienced limited regrowth of eyebrows and eyelashes after six months of deuruxolitinib, despite unchanged scalp hair, suggesting site-specific potential for hair regrowth in challenging cases.
This review discusses the approval of deuruxolitinib, an oral JAK inhibitor, by the FDA in July 2024 for treating severe alopecia areata in adults, highlighting its role as the third approved oral treatment option alongside baricitinib and ritlecitinib.
October 2025 in “Figshare” This meta-analysis found that deuruxolitinib significantly improved hair regrowth and patient satisfaction in those with moderate to severe alopecia areata compared to placebo, though it was associated with manageable side effects such as elevated creatinine kinase levels, headaches, and acne, especially at higher doses.
October 2025 in “Figshare” This systematic review and meta-analysis reported that deuruxolitinib is effective for hair regrowth and improving patient-reported outcomes in individuals with moderate to severe alopecia areata, but observed manageable treatment-emergent adverse events such as elevated creatinine kinase levels and headaches, particularly with higher doses.
September 2025 in “Journal of the American Academy of Dermatology” Deuruxolitinib improves anxiety and depression in severe alopecia areata patients.
September 2025 in “Journal of the American Academy of Dermatology” Deuruxolitinib significantly improves hair satisfaction in severe alopecia areata patients.
September 2023 in “Journal of the American Academy of Dermatology” CTP-543 is generally safe for treating alopecia areata.
September 2023 in “Journal of the American Academy of Dermatology” CTP-543 significantly improved eyebrow and eyelash regrowth and patient satisfaction in adults with alopecia areata.
Deuruxolitinib effectively promotes hair regrowth in alopecia areata.
July 2026 in “Journal of the American Academy of Dermatology” July 2026 in “Journal of the American Academy of Dermatology” 12 citations
,
December 2022 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” This review suggests that oral Janus kinase inhibitors are a promising treatment for alopecia areata in adults, showing significant hair regrowth with fewer side effects than conventional treatments, while PDE-4 inhibitors and biologics show limited efficacy.
10 citations
,
January 2023 in “Acta dermato-venereologica” In this study, deuruxolitinib and baricitinib showed promising efficacy in treating alopecia areata, but effectiveness varied with dosage and further trials are needed to confirm these results.
7 citations
,
August 2023 in “Journal of the American Academy of Dermatology” This source reports that the approval of baricitinib and ritlecitinib, which are JAK inhibitors, has marked a significant advancement in treating severe alopecia areata (AA), and suggests that additional treatments with new mechanisms may further improve patient outcomes in the future.
3 citations
,
May 2023 in “Clinical drug investigation” This study reviewed the safety of JAK inhibitors for alopecia areata, finding that common side effects included headache and acne, with varying risks for respiratory infections and no increased risk of serious adverse events.
2 citations
,
July 2023 in “Journal of cosmetic dermatology” In this study, JAK inhibitors like baricitinib and ruxolitinib were found to be more effective and caused fewer discontinuations due to adverse events in adults with alopecia areata compared to therapies like dupilumab and apremilast, highlighting the need for more high-quality comparative trials.
2 citations
,
April 2023 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” This systematic review evaluated the safety of JAK-inhibitors for alopecia areata, finding that most adverse events were mild and systemic formulations were well-tolerated; however, increased rates of certain infections and laboratory abnormalities were noted, with isolated severe cases but no fatal outcomes.
1 citations
,
January 2023 in “Cutis” This article highlights disparities in the prevalence of alopecia areata among people with skin of color and suggests this information could help dermatologic providers address challenges in treating this population.
JAK inhibitors, like baricitinib and ritlecitinib, show promise in treating alopecia areata effectively and safely.
July 2026 in “Advances in Therapy” This study found that clinicians treating alopecia areata prioritize JAK inhibitor treatments with higher efficacy and faster initial hair growth, regardless of dosing frequency, and preferred the treatment option with ritlecitinib 50-mg data the least among several blinded profiles.
July 2026 in “Quality in Sport” This review reports that Janus kinase inhibitors and regenerative therapies, such as exosomes and platelet-rich plasma, significantly improve scalp hair regrowth in moderate-to-severe alopecia areata, though challenges like high relapse rates and socioeconomic barriers remain, underscoring the need for personalized treatment protocols.